These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 18500259)
1. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259 [TBL] [Abstract][Full Text] [Related]
2. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ Mod Pathol; 2013 Mar; 26(3):435-47. PubMed ID: 23018874 [TBL] [Abstract][Full Text] [Related]
3. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445 [TBL] [Abstract][Full Text] [Related]
4. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408 [TBL] [Abstract][Full Text] [Related]
5. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset. Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281 [TBL] [Abstract][Full Text] [Related]
6. Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence. Qu X; Jeldres C; Glaskova L; Friedman C; Schroeder S; Nelson PS; Porter C; Fang M J Mol Diagn; 2016 Mar; 18(2):215-24. PubMed ID: 26752304 [TBL] [Abstract][Full Text] [Related]
7. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054 [TBL] [Abstract][Full Text] [Related]
8. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Fine SW; Gopalan A; Leversha MA; Al-Ahmadie HA; Tickoo SK; Zhou Q; Satagopan JM; Scardino PT; Gerald WL; Reuter VE Mod Pathol; 2010 Oct; 23(10):1325-33. PubMed ID: 20562851 [TBL] [Abstract][Full Text] [Related]
9. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence. Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400 [TBL] [Abstract][Full Text] [Related]
10. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038 [TBL] [Abstract][Full Text] [Related]
11. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Kluth M; Hesse J; Heinl A; Krohn A; Steurer S; Sirma H; Simon R; Mayer PS; Schumacher U; Grupp K; Izbicki JR; Pantel K; Dikomey E; Korbel JO; Plass C; Sauter G; Schlomm T; Minner S Mod Pathol; 2013 Jul; 26(7):975-83. PubMed ID: 23370768 [TBL] [Abstract][Full Text] [Related]
12. Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Krohn A; Freudenthaler F; Harasimowicz S; Kluth M; Fuchs S; Burkhardt L; Stahl P; C Tsourlakis M; Bauer M; Tennstedt P; Graefen M; Steurer S; Sirma H; Sauter G; Schlomm T; Simon R; Minner S Mod Pathol; 2014 Dec; 27(12):1612-20. PubMed ID: 24762546 [TBL] [Abstract][Full Text] [Related]
13. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607 [TBL] [Abstract][Full Text] [Related]
14. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769 [TBL] [Abstract][Full Text] [Related]
15. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067 [TBL] [Abstract][Full Text] [Related]
16. Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis. Heselmeyer-Haddad KM; Berroa Garcia LY; Bradley A; Hernandez L; Hu Y; Habermann JK; Dumke C; Thorns C; Perner S; Pestova E; Burke C; Chowdhury SA; Schwartz R; Schäffer AA; Paris PL; Ried T Am J Pathol; 2014 Oct; 184(10):2671-86. PubMed ID: 25131421 [TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer. Murphy SJ; Karnes RJ; Kosari F; Castellar BE; Kipp BR; Johnson SH; Terra S; Harris FR; Halling GC; Klein JL; Nasir A; Bergstrahl E; Rangel LJ; Sukov WR; Vasmatzis G; Cheville JC Mod Pathol; 2016 Feb; 29(2):143-56. PubMed ID: 26612463 [TBL] [Abstract][Full Text] [Related]
18. Frequency of PTEN alterations, TMPRSS2-ERG fusion and their association in prostate cancer. Fallahabadi ZR; Noori Daloii MR; Mahdian R; Behjati F; Shokrgozar MA; Abolhasani M; Asgari M; Shahrokh H Gene; 2016 Jan; 575(2 Pt 3):755-60. PubMed ID: 26424596 [TBL] [Abstract][Full Text] [Related]
19. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer. Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376 [TBL] [Abstract][Full Text] [Related]
20. Deletion of 8p is an independent prognostic parameter in prostate cancer. Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]